[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-thrombocytopenic-purpura\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-thrombocytopenic-purpura":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,85,113,137,166,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644385","atorvastatin-combined-with-nac-plus-romiplostim-for-management-of-itp-100644385",false,"NCT07662525","Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP","Atorvastatin Combined With N-Acetyl-L-Cysteine Plus Romiplostim for Management of Steroid-Resistant\u002FRelapsed Immune Thrombocytopenia","Inclusion Criteria:\n\n* Diagnosed with primary ITP;\n* Aged ≥18 years;\n* Patients with treatment failure or relapse after first-line corticosteriod therapy for ITP;\n* Platelet count \\\u003C30×10⁹\u002FL.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant;\n* Presence of active malignant tumors;\n* Active HBV, HCV or HIV infection;\n* Active infection requiring systematic treatment;\n* Leukemia, myelodysplastic syndrome, aplastic anemia, myelofibrosis or other hematological disorders that may cause thrombocytopenia;\n* History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure;\n* AST \\> 2 times the upper limit of normal (ULN), ALT \\> 2×ULN, or TBIL ≥ 1.5×ULN;\n* eGFR \\\u003C 50 mL\u002Fmin\u002F1.73m²;\n* Any other subjects deemed ineligible for enrollment by the investigator.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in adult patients with ITP following CS failure.",[26],"Immune Thrombocytopenic Purpura",[28,29,30,31,32],"immune thrombocytopenia","atorvastatin","N-acetyl-L-cysteine","romiplostim","sustained response off-treatment","NOT_YET_RECRUITING","2026-06-19",{"date":36,"type":37},"2026-06-23","ACTUAL",{"date":39,"type":20},"2026-06-01",{"date":41,"type":20},"2028-12-30",{"name":43,"class":44},"Peking University People's Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100635208","phase-1-safety-and-preliminary-efficacy-of-ctx112-in-adult-participants-with-relapsedrefractory-hematologic-autoimmune-disease-100635208","NCT07549698","Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed\u002FRefractory Hematologic Autoimmune Disease","A Phase 1\u002F2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed\u002FRefractory Hematologic Autoimmune Disease","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Participants must voluntarily sign a written informed consent and be willing and able to comply with all trial requirements.\n3. Adequate hematologic, renal, liver, cardiac and pulmonary function.\n4. Participants must agree to use acceptable methods of contraception.\n5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other trial procedures.\n6. Diagnosis of relapsed\u002Frefractory primary Immune Thrombocytopenic Purpura (ITP) or Warm Autoimmune Hemolytic Anemia (WAIHA)\n\nExclusion Criteria:\n\n1. Prior treatment with anti-CD19 therapy or any gene therapy or genetically modified cell therapy.\n2. Prior solid organ (e.g., heart, liver, kidney, lung) transplant or hematopoietic cell transplant.\n3. Severe active or history of central nervous (CNS) involvement.\n4. Presence of other active autoimmune disease or other conditions that are likely to pose increased safety risks and\u002For confound disease assessments, or pose significant risk to those receiving CAR T cell therapy.\n5. History of primary or secondary immunodeficiency.\n6. Presence or history of certain bacterial, viral or fungal infection\n7. Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence).\n8. Diagnosis of a genetic disorder associated with bone marrow failure or myelodysplastic syndrome.\n9. History or current diagnosis that requires uninterrupted, ongoing anticoagulation.\n10. Pregnant or lactating.\n11. Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.",{"count":54,"type":20},60,[56,57],"PHASE1","PHASE2","This is a single-arm, open-label, multicenter, ascending dose Phase 1\u002F2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed\u002Frefractory primary Immune Thrombocytopenia (ITP) and relapsed\u002Frefractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).",[60,61,62,26],"Warm Autoimmune Hemolytic Anemia (WAIHA)","ITP - Immune Thrombocytopenia","Warm Autoimmune Hemolytic Anemia",[64,65,66,67,68,69,70,71,26,72],"CD19","CTX112","Zugocabtagene geleucel","zugo-cel","CAR-T","ITP","warm autoimmune hemolytic anemia","wAIHA","Immune Thrombocytopenia","RECRUITING","2026-06-11",{"date":76,"type":37},"2026-06-15",{"date":78,"type":20},"2026-06",{"date":80,"type":20},"2033-12",{"name":82,"class":83},"CRISPR Therapeutics AG","INDUSTRY",3,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100607922","phase-2-a-study-of-efgartigimod-iv-in-participants-from-12-years-to-less-than-18-years-of-age-with-chronic-immune-thrombocytopenia-itp-100607922","NCT07194850","A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)","A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP","Inclusion Criteria:\n\n* Is aged 12 to less than 18 years when completing the informed consent process\n* Has a documented duration of primary ITP of more than 12 months on the date the informed consent process is complete\n* Has documented prior ITP treatment with at least 1 of the following treatments: corticosteroids, IVIg, anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RAs), or rituximab.\n* Has documented prior response, defined as 1 platelet count of ≥50 × 10\\^9\u002FL to at least 1 of the following ITP treatments: prednisone, other or nonspecified corticosteroids, IVIg, or anti-D immunoglobulin\n* Has documented insufficient response to a prior ITP treatment with corticosteroids, IVIg, anti-D immunoglobulin, TPO-RAs, rituximab, or splenectomy\n* Has documented mean platelet count of less than 30 x10\\^9\u002FL\n\nExclusion Criteria:\n\n* Secondary ITP according to the following definition by the International Working Group (IWG): all forms of immune-mediated thrombocytopenia except primary ITP\n* Nonimmune thrombocytopenia\n* ITP-associated critical or severe bleeding\n* History of hereditary thrombocytopenia","12 Years","17 Years",{"count":95,"type":20},24,[57,97],"PHASE3","The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).\n\nThe study consists of a double-blinded treatment period (DBTP) in which the participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV. At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first year open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second year (OLTP2). After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks.\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Fadvancejunior",[100,61,69,26,101,102,103],"Immune Thrombocytopenia (ITP)","Immune Thrombocytopenic Purpura ( ITP )","Idiopathic Thrombocytopenic Purpura","Idiopathic Thrombocytopenic Purpura (ITP)",{"date":105,"type":37},"2026-06-12",{"date":107,"type":37},"2025-10-20",{"date":109,"type":20},"2030-10",{"name":111,"class":83},"argenx",10,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100387362","phase-1-dose-dense-rituximab-for-high-risk-newly-diagnosed-acute-immune-thrombocytopenic-purpura-100387362","NCT04323748","Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura","The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura","NYMC207","Inclusion Criteria:\n\n* Age: Subjects must be ≥ 1 year and ≤ 21 years of age.\n* Diagnosis: Patients must have newly diagnosed ITP and a platelet count of ≤ 20 x 109 per Liter. Bone marrow aspirate and biopsy should be performed to rule out malignancy in the bone marrow.\n* High-risk features : In addition, patients must have one of more of the following high-risk criteria:\n\n  * Age ≥ 10 years\n  * Grade II-IV bleeding at diagnosis\n  * ANA positivity\n  * No history of preceding infection within 2 weeks prior to ITP diagnosis\n* Performance Status: Patients must have a performance status ≥ 50%. Use Karnofsky for patients \\> 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.\n* Prior Therapy\n\n  * Patients may not have received any treatment for ITP prior to start of therapy.\n  * Patients may not receive systemic steroids ≥ 0.5 mg\u002Fkg prednisone (or equivalent) within 2 weeks prior to diagnosis.\n* Concomitant Medications Restrictions:\n\n  * Steroids are only warranted as premedication prior to rituximab.\n  * Patients who receive thrombopoetic agonists, eltrombopag or romiplostim will be taken off protocol.\n* Organ Function Requirements\n\n  * Adequate Renal Function Defined As: estimated CrCl \\> 60 mL\u002Fmin or \\>30% of GFR for age based on the Schwartz formula\n  * Adequate Liver Function Defined As: AST and\u002For ALT less than 5 times the upper limit of normal, and\u002For direct bilirubin less than the 2 times of the upper limit of normal\n\nExclusion Criteria\n\n* Patients with a history of Grade III-IV allergic reaction to rituximab\n* Patients with bone marrow neoplastic infiltration\n* Patients with a history of hepatitis B infection\n* Pregnancy and Breast Feeding\n\n  * Female patients who are pregnant are ineligible (insert the reason: \"due to risks of fetal and teratogenic adverse events as seen in animal\u002Fhuman studies\" or \"since there is yet no available information regarding human fetal or teratogenic toxicities\").\n  * Lactating females are not eligible unless they have agreed not to breastfeed their infants.\n  * Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.","1 Year","21 Years",{"count":124,"type":20},20,[56],"The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.\n\nCorrelative studies will be performed as outlined in the appendices.\n\nQuality of Life will be measured using the KIT as outlined in the protocol.",[26],"2026-04-10",{"date":130,"type":37},"2026-04-15",{"date":132,"type":37},"2021-02-24",{"date":134,"type":20},"2027-07-31",{"name":136,"class":44},"New York Medical College",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100625705","development-and-prospective-validation-of-an-ai-model-for-prognosis-in-itp-patients-undergoing-coronary-revascularization-100625705","NCT07426107","Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization","An Artificial Intelligence-Enhanced Longitudinal Cohort Study to Optimize Revascularization Decisions in Patients With Coronary Artery Disease and Immune Thrombocytopenia (The ITP-CAD AI-REVASC Study)","ITP with CAD","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of primary Immune Thrombocytopenia (ITP) according to international working group criteria.\n3. Diagnosis of Coronary Artery Disease (stable angina or Acute Coronary Syndrome) confirmed by coronary angiography.\n4. The diagnosis of ITP must be established and documented prior to the diagnosis of CAD.\n5. Capable of providing informed consent (for prospective enrollment and data collection).\n\nExclusion Criteria:\n\n1. Secondary causes of thrombocytopenia (e.g., drug-induced, hematologic malignancy, hypersplenism, liver disease).\n2. Conditions requiring long-term therapeutic anticoagulation (e.g., atrial fibrillation, mechanical heart valve).\n3. Life expectancy less than 1 year due to non-cardiovascular disease.\n4. Inability to comply with follow-up.\n5. Inability to give informed consent.\n6. Pregnancy or breastfeeding.\n7. A history of Type 2 Myocardial Infarction prior to the index treatment decision.","90 Years",{"count":147,"type":20},600,"OBSERVATIONAL","This study employs a dual-cohort design to develop and validate a prognostic model for Major Adverse Cardiovascular Events (MACE) following revascularization in immune thrombocytopenia (ITP) patients with Coronary Artery Disease (CAD). The model will be developed and trained using a retrospective multi-center cohort (development\u002Ftraining cohort). Its performance will then be prospectively validated in a separate, consecutively enrolled prospective cohort (validation cohort). The goal is to create an AI-based tool to assist in personalized risk assessment and decision-making for this high-risk population.",[26,151],"Coronary Artery Disease",[28,153,154,155,156],"coronary artery disease","coronary revascularization","prognostic model","MACE","2026-02-15",{"date":159,"type":37},"2026-02-23",{"date":161,"type":20},"2026-02-25",{"date":163,"type":20},"2029-02-25",{"name":165,"class":44},"Xiao Hui Zhang",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100616802","physical-fitness-of-children-adolescents-and-young-adults-with-immune-thrombocytopenic-purpura-100616802","NCT07310342","Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura","Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura: a Prospective, Multicentre, Controlled National Study","ITP-CPET","Inclusion Criteria:\n\n* Children, adolescents and young adults aged 8 to 25 followed for ITPc\n* Patient referred as part of routine care by a CEREVANCE network expert physician to an exercise physiology laboratory for fitness assessment\n\nExclusion Criteria:\n\n* Presence of at least one contraindication to performing an exercise test\n\n  * Acute anemia \\\u003C 9g or poorly tolerated chronic anemia, fever, uncontrolled asthma, respiratory failure, acute myocarditis or pericarditis, uncontrolled arrhythmias causing symptoms or hemodynamic disturbance, uncontrolled heart failure, acute pulmonary embolism or pulmonary infarction,\n  * Patients with mental impairment leading to an inability to cooperate, as assessed by the physician during the history,\n  * Clinical examination abnormalities (heart murmur, rhythm disorders).\n* Opposition to participation expressed by the parent(s) or legal guardian(s) for minors (\\\u003C18 years) or by the patient.\n* Absence of social security","8 Years","25 Years",{"count":177,"type":20},53,[23],"Patients with chronic immune thrombocytopenic purpura (ITP) live with an anxiety-inducing risk of haemorrhage that is unpredictable over several months or years.\n\nThey also rate fatigue as one of the most frequent (48%) and most severe (73%) disabling symptoms, which contributes to a reduced quality of life \\[Cooper, 2021\\].\n\nIn this autoimmune disease targeting platelets, fatigue could be mediated by platelet and immunological abnormalities, and\u002For promoted by psychobehavioural determinants that are poorly understood in this chronic disease.\n\nSince 1980, the World Health Organisation has stated that functional capacity assessments best reflect the impact of chronic diseases on quality of life, with fatigue playing an important role. The association between fatigue and aerobic physical capacity, determined by maximum oxygen consumption (VO2max), has been demonstrated in several pathologies. It is often associated with the vicious circle of deconditioning, where the impact of the disease on cardiac, muscular and respiratory functions is intertwined with inactive or sedentary behaviours.\n\nAt the end of this vicious circle, adults have been shown to have an increased cardiovascular risk and a high prevalence of anxiety and depression syndromes.\n\nVO2max measured by cardiopulmonary exercise testing (CPET) is increasingly used in monitoring, as recommended by the French Society of Cardiology \\[Marcadet, 2018;Marcadet, 2019\\]. Our team (Amedro et al.) has set up a research programme on aerobic physical capacity and deconditioning to exercise in chronic childhood diseases and has just published the reference values for exercise tests in healthy paediatric populations, enabling the interpretation of VO2max results in sick children \\[Gavotto,2023\\].\n\nHowever, it has been demonstrated that the VO₂ plateau is not predominantly reached in healthy adults and is rarely reached (\\\u003C25%) in healthy children. \\[Armstrong, 1996 ; Åstrand, 1952 ; Rowland, 1992\\].\n\nThus, the highest oxygen consumption measurement (VO2pic) is often used instead of VO2max to define aerobic capacity. We will therefore use the concepts of VO2max and VO2pic in this study.\n\nThe first population studied by our team was children with congenital heart disease, who showed a significant reduction in their VO2max \\[Amedro, 2018\\]. Based on these results, a functional rehabilitation programme (QUALIREHAB) was set up and evaluated in a randomised controlled clinical trial \\[Amedro, 2019\\] . The data demonstrate its positive impact not only on VO2max, but also on quality of life. Aerobic physical capacity was assessed in chronic paediatric diseases without direct cardiac involvement.\n\nWe have also shown that VO2max declines more rapidly over time in children, adolescents and young adults who have survived childhood cancer \\[Gavotto, 2023\\] or in children with asthma \\[Moreau, 2023\\].\n\nTo date, no prospective controlled studies have reported on the level of aerobic physical capacity in children, adolescents and young adults with cITP.\n\nWe therefore hypothesise that fatigue in patients monitored for cITP could be correlated with a decrease in their aerobic physical capacity, causing these patients to enter a 'vicious cycle of deconditioning'. If this hypothesis is verified, an exercise rehabilitation programme could have a positive impact on quality of life, physical health and mental health",[26],[182,183,184,185],"Immune thrombocytopenic purpura (ITP)","Fatigue","Deconditioning","functional rehabilitation","2025-12-16",{"date":188,"type":37},"2025-12-30",{"date":190,"type":20},"2025-12-15",{"date":192,"type":20},"2026-12-22",{"name":194,"class":44},"University Hospital, Bordeaux",5,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100597547","prevalence-of-thyroid-disorders-in-patients-with-immune-thrombocytopenic-purpura-and-its-impact-on-treatment-100597547","NCT07059910","Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment","Inclusion Criteria:\n\n* ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.\n\n  * refractory ITP patients.\n\nExclusion Criteria:\n\n* patients with history of thyroidectomy\n\n  * patients with history of drug induced ITP\n  * patients with history of HCV, HBV and HIV infection.\n  * Patients who refuse to contribute in this study.",{"count":203,"type":20},100,"Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment",[26,206],"Thyroid Disorders","2025-07-13",{"date":209,"type":37},"2025-07-17",{"date":211,"type":20},"2025-07",{"date":213,"type":20},"2026-08-15",{"name":215,"class":44},"Assiut University"]